Search results

693 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Medical technologies guidance Remove Medical technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Social care guidelines Remove Social care guidelines filter

Osteoarthritis - naproxcinod [ID417]

In development [GID-TAG426] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]

In development [GID-TAG418] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

In development [GID-TAG456] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (acute lymphoblastic) - dasatinib [ID386]

In development [GID-TAG399] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Renal cell carcinoma (second line metastatic) - pazopanib [ID70]

In development [GID-TAG398] Expected publication date: 01 January 2011

Type

Technology appraisal guidance

Status

In development
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

In development [GID-TAG414] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Diabetic foot ulcers - new treatments [ID381]

In development [GID-TAG371] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous leg ulcers - new treatments [ID394]

In development [GID-TAG370] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism (VTE) - ximelagatran [ID396]

In development [GID-TAG378] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]

In development [GID-TA10209] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]

In development [GID-TA10690] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia [ID1083]

In development [GID-TA10260] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

Proposed [GID-TA10737] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag for treating chronic immune thrombocytopenia [ID3838]

Proposed [GID-TA10738] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588

In development [GID-TA10507] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ozanimod for treating moderate to severe ulcerative colitis [ID3841]

Proposed [GID-TA10732] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active ankylosing spondylitis [ID3848]

Proposed [GID-TA10735] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Type 2 diabetes in adults: management (update)

In development [GID-NG10160] Expected publication date: TBC

Type

NICE guideline

Status

In development
Diabetes update

In development [GID-NG10152] Expected publication date: TBC

Type

NICE guideline

Status

In development
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]

In development [GID-TA10646] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Selpercatinib for treating advanced thyroid cancer with RET alterations [ID3744]

In development [GID-TA10614] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]

In development [GID-TA10618] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1581]

Proposed [GID-TA10740] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

In development [GID-TA10596] Expected publication date: 15 December 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

In development [GID-TA10512] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

Proposed [GID-TA10535] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Galcanezumab for preventing cluster headache [ID1212]

In development [GID-TA10425] Expected publication date: 24 February 2021

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]

In development [GID-TA10615] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (brain metastases) - etirinotecan pegol [ID881]

In development [GID-TA10066] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

In development [GID-MT536] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

In development [GID-TA10484] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Antenatal care

In development [GID-NG10096] Expected publication date: 11 August 2021

Type

NICE guideline

Status

In development
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Baloxavir marboxil for treating influenza [ID1537]

In development [GID-TA10559] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

In development [GID-TA10544] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Apalutamide for treating prostate cancer [ID1534]

In development [GID-TA10423] Expected publication date: 26 May 2021

Type

Technology appraisal guidance

Status

In development
Baricitinib for treating moderate to severe atopic dermatitis [ID1622]

In development [GID-TA10562] Expected publication date: 03 March 2021

Type

Technology appraisal guidance

Status

In development
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]

In development [GID-TA10491] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Short bowel syndrome - teduglutide [ID885]

In development [GID-TA10048] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]

In development [GID-TA10466] Expected publication date: 28 April 2021

Type

Technology appraisal guidance

Status

In development
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]

In development [GID-TA10564] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

Proposed [GID-TA10722] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

In development [GID-TA10363] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

In development [GID-TA10609] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Sapropterin for treating phenylketonuria [ID1475]

In development [GID-TA10378] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]

Proposed [GID-TA10691] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed